Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was MXN1,269 Mil.
Sarepta Therapeutics's quarterly Accounts Payable
increased
from Sep. 2025 (MXN1,725 Mil) to Dec. 2025 (MXN5,057 Mil) but then
declined
from Dec. 2025 (MXN5,057 Mil) to Mar. 2026 (MXN1,269 Mil).
Sarepta Therapeutics's annual Accounts Payable
increased
from Dec. 2023 (MXN2,799 Mil) to Dec. 2024 (MXN4,472 Mil) and
increased
from Dec. 2024 (MXN4,472 Mil) to Dec. 2025 (MXN5,057 Mil).
Sarepta Therapeutics Accounts Payable Related Terms
Sarepta Therapeutics Accounts Payable Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
What does a Accounts Payable of MXN1,269 Mil mean?
Sarepta Therapeutics (MEX:SRPT) has a Accounts Payable of MXN1,269 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Accounts Payable too high?
Sarepta Therapeutics' current Accounts Payable is MXN1,269 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Accounts Payable compare to ZYME and BCAX?
Sarepta Therapeutics' Accounts Payable of MXN1,269 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Accounts Payable is MXN1,269 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,371.95, compared to a current price of MXN294.00 — trading 87.6% below its estimated fair value. The current Accounts Payable is MXN1,269 Mil. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Accounts Payable is MXN1,269 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN294.00 is trading 87.6% below its estimated GF Value™ of MXN2,371.95.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
Accounts Payable: MXN1,269 Mil
GF Value™: MXN2,371.95 vs. price of MXN294.00 (87.6% below fair value)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
